In this review, we will explore the implications of the CD47-SIRPα axis in AML pathophysiology, highlighting the novel therapeutic opportunities that exploit the blockage of this “don’t eat me” checkpoint. The gene discussed is SIRPA; the disease is acute myeloid leukemia.